Drugs / AMG 224
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02561962 | Nov 2015 → Nov 2018 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 224 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02561962 ↗ |
| Known as | Anti-bcma-mcc-dm1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594520 ↗ |
| Route | Intravenous | “Study medication will be administered once every 3 weeks by intravenous (IV) infusion.” NCT02561962 ↗ |